Hemophilia disease forecast and market analysis to 2035
|出版日期||內容資訊||英文 86 Pages
|到2035年的血友病市場分析和預測 Hemophilia disease forecast and market analysis to 2035|
|出版日期: 2020年07月14日||內容資訊: 英文 86 Pages||
2018年全球診斷出的血友病A人數約為187,750，而血友病B的人數約為35,950。到2027年，預計患病率將分別增加到193,730和38,570。此外，2018年全球範圍內已確診的von Willebrand病（VWD）病例數約為82,550，預計到2027年將增至86,150。迄今為止，全長重組凝血因子VIII產品Advate and Kogenate和凝血因子IX產品BeneFIX佔據了血友病治療領域的主導地位，並佔據了大部分市場份額。但是，這些藥物已被更頻繁地轉換為新一代產品，並且延長的半衰期製劑（EHL）和Hemlibra穩步佔領了市場佔有率。
Hemophilia is a relatively rare hereditary genetic disorder characterized by an inability to produce a clot capable of stopping bleeding. Patients without hemophilia who develop inhibitors against clotting factor VIII or factor IX are diagnosed as having acquired hemophilia A or B, respectively. Another disease associated with blood coagulation dysfunction is von Willebrand disease, which is caused by a deficiency in von Willebrand factor. Although von Willebrand disease is more common than hemophilia, it is relatively less severe.ilia, it is relatively less severe.
Latest Key Takeaways
Datamonitor Healthcare estimates that in 2018, there were approximately 180,750 diagnosed prevalent cases of hemophilia A and 35,950 diagnosed prevalent cases of hemophilia B worldwide. These figures are forecast to increase to 193,730 cases and 38,570 cases, respectively, by 2027. There were approximately 82,550 diagnosed prevalent cases of von Willebrand disease (VWD) worldwide in 2018, which is forecast to increase to 86,150 cases by 2027.
Current treatments are largely focused on replacing factor VIII or IX, the deficiency of which causes hemophilia A or B, respectively. Recombinant factor VIII and IX are at the top of algorithms in the US and EU treatment guidelines. Until now, full-length recombinant factor VIII agents Advate and Kogenate, and the factor IX agent BeneFIX, have dominated the hemophilia space and hold the largest portion of market share. However, these drugs have been steadily losing market share to extended half-life recombinant factor products (EHLs) and Hemlibra, as physicians switch patients to newer-generation products with improved dosing frequencies. In 2019, sales of Advate almost halved due to fierce competition primarily from Roche's Hemlibra, which was awarded a label expansion in the US and EU in the first quarter of 2019.
The therapeutic strategies for hemophilia were revolutionized after the introduction of replacement factors during the late 1990s and early 2000s, which were followed by EHLs over the past decade. Currently, the hemophilia market is undergoing a third revolution with an anticipated shift towards alternative coagulation promoters and gene therapy.
While the 2017 launch of Roche's Hemlibra for the treatment of hemophilia A patients with factor VIII inhibitors did not make a large impact on the hemophilia market, the extension of its US and EU labels in 2018 to include hemophilia A patients without inhibitors triggered a sharp uptake in sales. Hemlibra has captured market share from a host of replacement factors and EHLs, and is set to achieve market-leader status over the forecast period. Hemlibra is clinically more attractive than rival products because of its novel inhibitor-independent mechanism of action, its fortnightly dosing schedule, and its ability to be self-administered subcutaneously in a market dominated by intravenous agents.
There are a number of pipeline candidates in the hemophilia space which may make a significant impact in the market over the forecast period. Based on discussions with key opinion leaders (KOLs), Datamonitor Healthcare expects that Roche's Hemlibra will further extend its lead in the hemophilia space, having captured market-leader status from Takeda's Advate in 2019. Gene therapies are expected to have initially muted uptake because of a high upfront cost for payers ($2m-$3m) and an initial reluctance from prescribers owing to uncertainty over their long-term efficacy and safety.
In the hemophilia B space, pipeline alternative coagulation promoters such as the siRNA agent fitusiran, and the tissue factor pathway inhibitors (TFPIs) concizumab and marstacimab, may struggle to gain uptake due to safety concerns. These drugs meet the need for an effective therapy for hemophilia B patients with inhibitors, provide a more convenient subcutaneous route of administration, and, in the case of fitusiran, provide an impressive once-monthly dosing regimen. However, whether these drugs will come to market is still unclear given substantial safety concerns. While development of fitusiran has continued after a preventable fatality in Phase II trials, continued development of Novo Nordisk's concizumab may be unlikely after three thrombotic adverse events in Phase III trials, representing another setback for the TFPI class. Concerning safety events have not yet been observed in a single Phase I/II study of marstacimab, but the safety of the class as a whole is now in doubt. Given these safety concerns and a lack of physician familiarity, it seems unlikely these drugs will rival recombinant factor IX market leaders BeneFIX and Alprolix for the treatment of hemophilia B patients without inhibitors.
Roctavian (valoctocogene roxaparvovec) is the most advanced gene therapy in the hemophilia A space, and assuming EU and US approvals in Q3 2020, BioMarin is expected to launch the product at a price of $2m-$3m per patient. The extremely high upfront cost of Roctavian will be a significant deterrent to uptake, and we expect its initial use to be limited to severe hemophilia patients on chronic prophylaxis therapy. While gene therapy meets the high unmet need of a long-term therapy, with a projected eight-year interval between doses, Roctavian may face initial payer resistance due to the lack of long-term safety and efficacy data as the follow-up period in current studies has been limited to three years.